|
|
|
|
|
EnbrelNavigation: Home > Class Action Law> Enbrel
|
|
Enbrel, a genetically engineered protein, was approved to treat patients with symptoms of moderate to severe, active RA who have not responded well to other treatments. It can significantly reduce pain and swollen joints in people disabled with RA, an autoimmune disease that affects more than two million Americans. The FDA is advising physicians about new safety concerns regarding the use of etanercept (Enbrel), a product recently approved to treat moderate to severe rheumatoid arthritis (RA). New postmarketing reports indicate that certain patients receiving Enbrel have developed serious infections, including sepsis, and that several of these patients have died from their infections. Since the drug's approval, 30 of the estimated 25,000 patients treated with Enbrel are reported to have developed serious infections, including sepsis. Six of these patients died within two to sixteen weeks after starting treatment. A number of these RA patients had a history of chronic or recurrent infections, pre-existing infections, diabetes, or other conditions that predisposed them to infections.
If you have experienced severe side effects due to this medication, seek an attorney, or find a firm devoted to class actions against the manufacturer of Enbrel.
|
|
|
Sponsored Ads |
|
|
Sponsored Links |
|
|
|